Try our Advanced Search for more refined results

In re HIV Antitrust Litigation

Track this case

Case overview

Case Number:

3:19-cv-02573

See also:

Court:

California Northern

Nature of Suit:

Anti-Trust

Multi Party Litigation:

Class Action

Judge:

Edward M Chen

Firms

Companies

Government Agencies

Sectors & Industries:

  1. June 16, 2023

    Harvard Profs Battle Over $1.5B Antitrust Damages Estimate

    A Harvard University professor emeritus testifying in a federal antitrust trial Friday over claims Gilead and Teva illegally delayed generic versions of HIV medications told a California jury that the suit's end-payor classes were overcharged $1.5 billion — provoking Gilead to challenge that amount at cross-examination using opinions from its own Harvard expert.

  2. June 14, 2023

    Ex-FDA Official Tells Antitrust Jury Generic Rivals Were Ready

    A former FDA official took the stand Wednesday in a federal antitrust trial over claims Gilead struck a deal with Teva to illegally delay generic versions of its blockbuster HIV medications until 2020, testifying that several generics manufacturers were ready to launch their versions in early 2018.

  3. June 13, 2023

    Gilead-Teva Patent Deal Cost Drug Buyers Over $2B, Jury Told

    A retired Harvard Medical School health economics professor testified Tuesday in a California federal antitrust trial over claims that Gilead and Teva struck an illegal "pay for delay" patent deal over two HIV medications, saying the agreement "delayed competition and imposed massive harms on purchasers," costing them over $2 billion.

  4. June 09, 2023

    Gilead-Teva IP Deal Struck Despite Invalidity Issues, Jury Told

    Two experts took the stand Friday on behalf of indirect drug buyers in a California federal antitrust trial over claims Teva struck an illegal "pay for delay" patent deal with Gilead over two HIV medications, testifying that Gilead's patents covered obvious technology and Teva knew that before entering the deal.

  5. June 07, 2023

    Teva Atty Says Gilead Deal Followed Bad News On FDA Filing

    A top Teva lawyer testified Wednesday in an antitrust trial over claims that the company struck an illegal "pay for delay" deal with Gilead over two HIV medications, saying Teva reached the mid-trial settlement just days after learning the FDA was unlikely to give it first-filer rights to exclusively sell its generic versions.

  6. June 06, 2023

    Ex-Gilead GC Says He Didn't Calculate Teva's Gain In IP Deal

    Gilead's ex-general counsel testified Tuesday in a "pay for delay" antitrust trial over its HIV drug patent deal with Teva, saying he never calculated a dollar value for the royalty-free license Gilead gave Teva, which ultimately gave Teva six months on the generics market ahead of competitors.

  7. June 05, 2023

    Ex-Gilead VP Says Execs Gamed Out Truvada Generic Date

    A former Gilead executive testifying Monday in an antitrust trial over claims Gilead and Teva illegally delayed generic versions of its blockbuster HIV drugs until 2020 told jurors that before the pharmaceutical makers' deal, Gilead executives discussed the possibility that generic competition for Truvada could come as early as 2017.

  8. May 30, 2023

    Teva's Drug IP Deal With Gilead Not Pay To Delay, Jurors Hear

    Teva's counsel defended the generic-drug maker Tuesday during opening statements in a California trial over claims it reached an anticompetitive deal with Gilead over two HIV medications, saying it settled a patent suit brought by Gilead because it risked losing, not to score an illegal "pay for delay" deal.

  9. May 25, 2023

    Gilead, Teva Ink 11th-Hour HIV Antitrust Deal With Pharmacies

    With openings set to begin Thursday in an antitrust trial over claims Gilead and Teva illegally inflated HIV drug prices, the two drugmakers struck a last-minute deal with major pharmacies, and Gilead settled with direct purchasers — leaving indirect purchasers and others to take their claims to a California federal jury.

  10. May 24, 2023

    Jurors Weren't Barred Over Race, Gilead Antitrust Judge Says

    A California federal judge overseeing an antitrust trial over claims that Gilead and Teva inflated HIV drug prices has rebuffed the pharmaceutical giants' Batson challenge alleging that the plaintiffs had improperly sought to exclude Asian jurors, noting that several Asian Pacific Islanders were picked for the jury.